TO-210 Phase 1 Study

A Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of TO-210 5% in Japanese Subjects With Acne Vulgaris

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071230128

Enrollment

Registered

2024-03-15

Start date

2024-03-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Interventions

Cohort 1-3 Single dose application of TO-210 5% or Placebo Cohort 4 Multiple dose application of TO-210 5% or Placebo once daily for 7 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Japanese patients aged between 18 and 49 years at informed consent -Patients with facial acne valgaris with an Investigator's Global Assessment (IGA) score of 2-4 -Patients with 5-100 inflammatory lesions (papules, pustules) on the face (including the nose)

Exclusion criteria

Exclusion criteria: -Patients with a history of serious diseases such as brain, liver, kidney, heart, lung, digestive system, blood, endocrine system, metabolic system and mental system, or those currently under treatment -Patients whose acne symptoms suddenly changed within at least 12 weeks before screening -Patients with other skin diseases (e.g., urticaria, atopic dermatitis) or skin infections (bacterial, fungal, or viral) that might interfere with the evaluation of acne or TO-210 safety, except for tinea pedis

Design outcomes

Primary

Measure	Time frame
Safety, Pharmacokinetics	—

Contacts

Public ContactKensuke Natsui

Torii Pharmaceutical Co.,Ltd.

kensuke.natsui@torii.co.jp+81-3-3231-6583

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026